Biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN) reported on Friday positive high-level results from the global Phase III DUO-E trial showing that Imfinzi (durvalumab), when combined with platinum-based chemotherapy followed by either Imfinzi plus Lynparza (olaparib) or Imfinzi alone as maintenance therapy, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients with advanced or recurrent endometrial cancer.
This marks the first Phase III trial to demonstrate clinical benefit in this context by combining immunotherapy and PARP inhibition. The combination of Imfinzi and Lynparza as maintenance treatment showed greater clinical benefit.
AstraZeneca noted that although overall survival data were immature during the analysis, a favourable trend was observed for both treatment regimens.
Endometrial cancer is the sixth most common cancer in women globally, and there is a need for novel treatment options.
The safety and tolerability profiles of Imfinzi plus chemotherapy and Imfinzi in combination with Lynparza were consistent with prior trials and known profiles of the medicines.
Chroma Medicine names new director
Medivir to present promising Fostrox data for liver lancer at ESMO Congress
TME Pharma to present NOX-a12 glioblastoma trial results at ESMO Congress 2024
Full-Life Technologies signs licence agreement with SK Biopharmaceuticals
Hoth Therapeutics adds three centres to clinical trial for cancer patients
SFA Therapeutics names new chief operating officer
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation